The purpose of this proposal is to establish a new Alzheimer's Disease Research Center (ADRC) at the University of California, San Francisco (UCSF). The UCSF ADRC proposes to integrate basic science and clinical resources to investigate the clinical, molecular, neuropathological and neuroimaging features of Alzheimer's disease (AD), non-AD dementias, and mild-cognitive impairment (MCI). The proposed ADRC has two overarching aims: 1) to bridge the gap between laboratory and clinical studies in dementia and aging and 2) to explore the early, heterogeneous and overlapping presentations of different neurodegenerative disorders. The new ADRC will help integrate the strong UCSF basic science and clinical neurology programs in an effort to promote new discoveries. To address these aims, the ADRC will be organized around five Cores and three Projects. The Administrative, Education and Outreach Core will provide support overall management, training, and minority outreach. The Clinical Core will maintain well characterized cohorts of patients with AD, frontotemporal lobar degeneration, progressive supranuclear palsy, corticobasal degeneration, Creutzfeldt-Jakob disease, and MCI. Atypical presentations of AD and MCI will be studied, with special interest in patients with isolated language or executive symptoms. The Data Management and Biostatistical Core will assure standardized collection, validation, and novel statistical analysis of data. The Neuropathology Core will obtain autopsy material from the ADRC cohorts and facilitate clinicopathological studies. The Neuroimaging Core will use 4 Tesla MRI to investigate differential diagnosis of dementia. One Project will develop novel reagents to study PrPC structure and evaluate the ability of proteins to detect PrPsc in mice. A second Project will evaluate the relationship between cognitive deficits and calcium-dependent proteins in mice and humans. The final Project will use data from a unique cohort of 1061 MCI cases from the State of California's Alzheimer's Disease Centers to identify outcomes, risk factors, and MCI subtypes. This Project will also evaluate amnestic and nonamnestic (language, executive and mixed) MCI patients in an effort to better define the heterogeneity of MCI. The new ADRC will, therefore, build upon existing strengths at UCSF to promote unique studies of AD and non-AD dementias and MCI that will have an impact both locally and nationally.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG023501-04
Application #
7248814
Study Section
Special Emphasis Panel (ZAG1-ZIJ-7 (J4))
Program Officer
Phelps, Creighton H
Project Start
2004-05-15
Project End
2009-03-31
Budget Start
2007-04-15
Budget End
2008-03-31
Support Year
4
Fiscal Year
2007
Total Cost
$1,423,854
Indirect Cost
Name
University of California San Francisco
Department
Neurology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
McKeever, Paul M; Schneider, Raphael; Taghdiri, Foad et al. (2018) MicroRNA Expression Levels Are Altered in the Cerebrospinal Fluid of Patients with Young-Onset Alzheimer's Disease. Mol Neurobiol 55:8826-8841
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25
Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
La Joie, Renaud; Bejanin, Alexandre; Fagan, Anne M et al. (2018) Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 90:e282-e290
Wang, Chengzhong; Najm, Ramsey; Xu, Qin et al. (2018) Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat Med 24:647-657
Bettcher, Brianne M; Johnson, Sterling C; Fitch, Ryan et al. (2018) Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage. J Alzheimers Dis 62:385-397
Iaccarino, Leonardo; Tammewar, Gautam; Ayakta, Nagehan et al. (2018) Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. Neuroimage Clin 17:452-464
Eser, Rana A; Ehrenberg, Alexander J; Petersen, Cathrine et al. (2018) Selective Vulnerability of Brainstem Nuclei in Distinct Tauopathies: A Postmortem Study. J Neuropathol Exp Neurol 77:149-161

Showing the most recent 10 out of 590 publications